376 related articles for article (PubMed ID: 29038234)
1. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
[TBL] [Abstract][Full Text] [Related]
2. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
[TBL] [Abstract][Full Text] [Related]
3. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
4. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
5. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
[TBL] [Abstract][Full Text] [Related]
7. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
[TBL] [Abstract][Full Text] [Related]
8. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.
Bianchi A; De Marinis L; Fusco A; Lugli F; Tartaglione L; Milardi D; Mormando M; Lassandro AP; Paragliola R; Rota CA; Della Casa S; Corsello SM; Brizi MG; Pontecorvi A
J Endocrinol Invest; 2011 Oct; 34(9):692-7. PubMed ID: 22067307
[TBL] [Abstract][Full Text] [Related]
9. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
[TBL] [Abstract][Full Text] [Related]
12. A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.
Blot K; Duchateau L; Lescrauwaet B; Liyanage N; Ray D; Mirakhur B; Vinik AI
Patient Relat Outcome Meas; 2019; 10():335-343. PubMed ID: 31754316
[TBL] [Abstract][Full Text] [Related]
13. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
17. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Caplin ME; Pavel M; Phan AT; Ćwikła JB; Sedláčková E; Thanh XT; Wolin EM; Ruszniewski P;
Endocrine; 2021 Feb; 71(2):502-513. PubMed ID: 33052555
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
Sidéris L; Dubé P; Rinke A
Oncologist; 2012; 17(6):747-55. PubMed ID: 22628056
[TBL] [Abstract][Full Text] [Related]
19. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Lucas T; Astorga R;
Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]